BRPI0706379A2 - tratamento de hepatite viral - Google Patents

tratamento de hepatite viral Download PDF

Info

Publication number
BRPI0706379A2
BRPI0706379A2 BRPI0706379-2A BRPI0706379A BRPI0706379A2 BR PI0706379 A2 BRPI0706379 A2 BR PI0706379A2 BR PI0706379 A BRPI0706379 A BR PI0706379A BR PI0706379 A2 BRPI0706379 A2 BR PI0706379A2
Authority
BR
Brazil
Prior art keywords
interferon
patient
compound
nitazoxanide
treatment
Prior art date
Application number
BRPI0706379-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jean-Francois Rossignol
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of BRPI0706379A2 publication Critical patent/BRPI0706379A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BRPI0706379-2A 2006-01-09 2007-01-09 tratamento de hepatite viral BRPI0706379A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75703606P 2006-01-09 2006-01-09
US60/757.036 2006-01-09
PCT/US2007/000574 WO2007081974A2 (en) 2006-01-09 2007-01-09 Viral hepatitis treatment

Publications (1)

Publication Number Publication Date
BRPI0706379A2 true BRPI0706379A2 (pt) 2011-03-22

Family

ID=38257004

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0706379-2A BRPI0706379A2 (pt) 2006-01-09 2007-01-09 tratamento de hepatite viral

Country Status (17)

Country Link
US (3) US8633230B2 (cg-RX-API-DMAC7.html)
EP (1) EP1976516B9 (cg-RX-API-DMAC7.html)
JP (2) JP5185826B2 (cg-RX-API-DMAC7.html)
CN (1) CN101448497B (cg-RX-API-DMAC7.html)
AP (1) AP2907A (cg-RX-API-DMAC7.html)
AU (1) AU2007204963B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0706379A2 (cg-RX-API-DMAC7.html)
CA (1) CA2636527C (cg-RX-API-DMAC7.html)
DK (1) DK1976516T3 (cg-RX-API-DMAC7.html)
EA (1) EA015560B1 (cg-RX-API-DMAC7.html)
ES (1) ES2422556T3 (cg-RX-API-DMAC7.html)
IL (1) IL192548A (cg-RX-API-DMAC7.html)
MX (1) MX2008008723A (cg-RX-API-DMAC7.html)
NZ (1) NZ569507A (cg-RX-API-DMAC7.html)
UA (1) UA100840C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007081974A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806310B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235490A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
CA2694440A1 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
MX381895B (es) * 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
AU2010226857B2 (en) 2009-03-20 2016-07-14 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
US9333193B2 (en) 2010-09-20 2016-05-10 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
CN102805747B (zh) * 2011-06-01 2013-09-18 漳州片仔癀药业股份有限公司 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9498441B2 (en) 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
JP6633092B2 (ja) 2014-11-11 2020-01-22 ロマーク ラボラトリーズ,リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
HK1250945A1 (zh) 2016-03-31 2019-01-18 罗马克实验室有限公司 用於治疗病毒性感染的噻唑化物化合物
SI3442580T1 (sl) * 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni
US20170290814A1 (en) * 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
WO2018140504A1 (en) 2017-01-24 2018-08-02 Patel Manoj K Compositions and methods for blocking sodium channels
EP3573614B1 (en) * 2017-01-27 2024-11-20 Genfit Pharmaceutical compositions for combination therapy
SG11201907673YA (en) * 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
US11547699B2 (en) 2017-11-17 2023-01-10 Hubert Köster [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
US12208087B2 (en) 2019-04-09 2025-01-28 Genfit Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ,リミティド カンパニー チゾキサニドおよび2-ヒドロキシ-n-(5-クロロ-1,3-チアゾル-2-イル)ベンズアミド(rm-4848)とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびn-メチルピペラジンの結晶塩
IL300801A (en) 2020-08-24 2023-04-01 Romark Laboratories Lc Use of thiazolides against the corona virus
KR20240006588A (ko) * 2021-05-11 2024-01-15 장피트 패혈증의 치료에서의 니타족사나이드
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
SI0755386T1 (en) * 1994-04-13 2002-10-31 Romark Laboratories, L.C. Benzamide derivative, compositions containing said derivative and use thereof
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
SI20149B (en) 1997-05-07 2001-08-31 Romark Lab Lc Pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
DE69901321T2 (de) * 1998-05-15 2002-12-12 Schering Corp., Kenilworth Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
US5925622A (en) 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
EP1562617B1 (en) 2002-10-29 2006-12-20 Council of Scientific and Industrial Research New use of pipataline
US7081260B2 (en) 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
CA2520853A1 (en) * 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
MX381895B (es) * 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.

Also Published As

Publication number Publication date
CA2636527C (en) 2016-05-17
US8633230B2 (en) 2014-01-21
AU2007204963A1 (en) 2007-07-19
CN101448497B (zh) 2013-07-10
CN101448497A (zh) 2009-06-03
US20140112888A1 (en) 2014-04-24
AP2907A (en) 2014-05-31
UA100840C2 (ru) 2013-02-11
ES2422556T3 (es) 2013-09-12
EP1976516B9 (en) 2013-10-30
CA2636527A1 (en) 2007-07-19
AP2008004550A0 (en) 2008-08-31
JP2010070566A (ja) 2010-04-02
IL192548A0 (en) 2009-02-11
WO2007081974A2 (en) 2007-07-19
EA015560B1 (ru) 2011-08-30
EA200870164A1 (ru) 2008-12-30
EP1976516B1 (en) 2013-04-24
JP2009522371A (ja) 2009-06-11
HK1123733A1 (en) 2009-06-26
WO2007081974A3 (en) 2008-01-17
USRE47404E1 (en) 2019-05-28
ZA200806310B (en) 2009-12-30
US20070167504A1 (en) 2007-07-19
AU2007204963B2 (en) 2012-09-27
IL192548A (en) 2015-08-31
US9107913B2 (en) 2015-08-18
DK1976516T3 (da) 2013-07-15
JP5185826B2 (ja) 2013-04-17
EP1976516A2 (en) 2008-10-08
NZ569507A (en) 2011-11-25
MX2008008723A (es) 2008-09-26
EP1976516A4 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
USRE47404E1 (en) Viral hepatitis treatment
JP2009522371A5 (cg-RX-API-DMAC7.html)
KR102073536B1 (ko) 데옥시콜린산 및 그의 염들의 제형물들
CN106692162A (zh) 用于辐射伤和化学治疗伤的局部活性类固醇
CN101495115A (zh) 组合治疗
Peters et al. High-dose cytosine arabinoside: pharmacological and clinical aspects
US9295669B2 (en) Combination therapy for proliferative disorders
SI21079A (sl) Formulacija, ki povečuje mobilizacijo
EP1057489B1 (en) Use of midkine family proteins in the treatment of ischemic diseases
JPH11269076A (ja) 抗線維化剤
EP4680263A1 (en) Annexin a1 administration regime
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
EA009209B1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
CN120884592B (zh) 靶向lif-lifr的化合物在制备促进组织抗纤维化的药物中的用途
HK1123733B (en) Viral hepatitis treatment
JP2004508419A (ja) 心電図のqt間隔の短縮
JP4287523B2 (ja) 抗腫瘍剤
TW202606762A (zh) 治療t細胞淋巴瘤之組合物及方法
JP2688733B2 (ja) 消化管粘膜障害の予防及び治療剤
CN114177272A (zh) Mm07在制备治疗矽肺的药物中的应用
JP2005504009A (ja) 心臓保護のためのアデノシンa1/a2アゴニストの投与のタイミングおよび継続
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
TW201110976A (en) Medicinal agent and method for treatment of intractable chronic hepatitis c

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time